Connect with us:

Home
Conditions
Resource Centers
Drug Updates
Professional Topics
Practice Management
Resources
About Us
Advertise
Search

You are here: Home / Articles / Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz

Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz

June 22, 2016 • By Michele B. Kaufman, PharmD, BCGP

Tweet
Email

Print-Friendly Version / Save PDF

You Might Also Like

FDA Update: Possible Heart Risks with Clarithromycin; Apadaz Receives FDA Approval
Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
FDA Restricts Use of Systemic Fluoroquinolones Due to Side Effects & Will Review Application of Apadaz for Pain

Also By This Author

FDA Updates Boxed Warning of Benzodiazepines, Adding Risks for Abuse & Addiction

Pages: 1 2 | Single Page

Filed Under: Analgesics, Conditions, Drug Updates Tagged With: Benzhydrocodone hydrochloride, Chronic pain, FDA, Food and Drug Administration, Guidelines, Osteoporosis, postmenopause, Regulation

You Might Also Like:

FDA Update: Possible Heart Risks with Clarithromycin; Apadaz Receives FDA Approval
Biosimilar Update: ACR Says FDA Draft Guidance Is Promising & Biosimilar to Humira (Adalimumab) Enters Regulatory Review
FDA Restricts Use of Systemic Fluoroquinolones Due to Side Effects & Will Review Application of Apadaz for Pain
FDA Update: Committees Recommend Approvals for Abuse-Deterrent Opioid & Brodalumab

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

Connect with us:

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)